Several previous papers present that therapeutic radionuclides, 90Y- and 177Lu-labeled anti-EGFR antibodies have the therapeutic potential to cetuximab-resistant HNSCC tumor model [19, 20]. This evidence concerns the gene EGFR and neoplasm.